The architecture powering Zero Trust at the edge

Tern plc

The shift to Zero Trust security has placed a new spotlight on the most fundamental yet overlooked layer of the digital ecosystem: device identity. For enterprises managing vast fleets of connected assets, the moment of onboarding is no longer a technical footnote, it is the critical juncture where long-term trust, compliance, and resilience begin.

What has long been treated as an administrative step in the supply chain has now become a strategic control point. Weak or reused device identities have been the unseen entry point for some of the most serious operational breaches, from energy grid outages to compromised medical systems. Yet, the tide is turning. Advances in automated identity provisioning now enable enterprises to establish verifiable trust at the very edge, embedding security directly during manufacturing and onboarding rather than layering it on afterwards.

At the centre of this evolution is Device Authority’s KeyScaler® platform, which automates the creation and management of strong, unique device identities at industrial scale. Each identity can be anchored in hardware through Trusted Platform Modules or secure elements, or dynamically generated via Dynamic Device Key Generation when such components are absent.

The true strength of Zero Trust, however, lies in the ongoing validation of identity rather than its initial establishment. Device Authority’s partnership with Olympus integrates these trust anchors into identity and access management frameworks where policies continuously adapt to device health, behaviour, and operational context.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Device Authority targets secure digital infrastructure for smart ports

Device Authority's Smart, Green Port Blueprint shows how secure device management can support the wider rollout of connected infrastructure across modern ports.

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Search